Alcanza Clinical Research has acquired Accel Research Site Network and its 22 trial sites located across the Southeast U.S.
Spread across Florida, Alabama and Georgia, the sites break down into eight clinical research units and 14 embedded sites located in healthcare settings, Alcanza said in a July 18 press release. Financial terms of the purchase weren’t disclosed.
The acquisition includes two Florida sites located in Ormond Beach and Edgewater that Accel picked up in April. Under the terms of the Alcanza deal, the Accel sites will all continue to operate under their current branding.
“The addition of Accel to the Alcanza network is part of our strategy to operate with greater scale and therapeutic specialization to reach more patient populations who are not traditionally presented with research participation opportunities,” Alcanza CEO Carlos Orantes said in the release.
Alcanza, which operates sites in Florida, Massachusetts, Michigan, New Hampshire, South Carolina and Virginia, inked a partnership deal in late May with software provider Climb to streamline digital clinical trials. Alcanza specializes in psychiatry, neurology, dermatology and infectious disease.